MannKind Corporation
MNKDHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeMannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. Valued at $1.03B, MNKD is a small-cap name in its sector. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Market Cap
$1.03B
Beta
1.08
P/E (TTM)
—
P/E (Fwd)
23.63
EPS (TTM)
$-0.14
EPS (Fwd)
$0.14
ROE
—
ROA
0.8%
Cash
$111.1M
Total Debt
$433.8M
Free CF
$40.3M
52W Change
-41.1%
Annual Financials
Cash vs Debt
Where MNKD stands vs its 150-day and 200-day moving averages
As of the October 14, 2026 close, MNKD finished 12.36% below its 150-day moving average ($3.48) and 21.59% below its 200-day moving average ($3.89). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MNKD overbought or oversold?
At the October 14, 2026 close, MNKD's RSI(14) was 41.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $111.1M in cash, though total debt stands at $433.8M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $40.3M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROA of 0.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $99.8M (2022) to $349.0M (2025), reflecting a 250% increase over the period.
As with any equity investment, MNKD carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for MannKind Corporation and its sector.